Therapeutic Asset Ratings

303 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Pacritinib Myeloproliferative Neoplasm	University of Washington	P2	CC (46)
Pacritinib Myeloproliferative Neoplasm, Unclassifiable	University of Washington	P2	CC (46)
Pacritinib Acquired Polycythemia Vera	University of Washington	P2	CC (46)
Pacritinib Primary Myelofibrosis	University of Washington	P2	CC (46)
Trabedersen Lung Cancer	University of Washington	P2	CC (46)
Cyclophosphamide Cognitive Disorder	University of Washington	P1/2	CC (46)
BICARBONATE ION Prostate Cancer	University of Washington	P1/2	CC (44)
c105 Breast Carcinoma	University of Washington	P1	CC (43)
cd105/yb-1/sox2/cdh3/mdm2-polyepitope plasmid dna vaccine Breast Carcinoma	University of Washington	P1	CC (43)
Dostarlimab BRCA-Associated Malignant Neoplasm	University of Washington	P1	CC (43)
Dostarlimab Familial Ovarian Carcinoma	University of Washington	P1	CC (43)
Dostarlimab Hereditary Breast Carcinoma	University of Washington	P1	CC (43)
Dostarlimab Fallopian Tube Carcinoma	University of Washington	P1	CC (43)
Dostarlimab Exocrine Pancreatic Carcinoma	University of Washington	P1	CC (43)
Eloxatin ALK-Positive Large B-Cell Lymphoma	University of Washington	P1	CC (43)
ETOPOSIDE ALK-Positive Large B-Cell Lymphoma	University of Washington	P1	CC (43)
Glofitamab ALK-Positive Large B-Cell Lymphoma	University of Washington	P1	CC (43)
Glofitamab B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma And Classical Hodgkin Lymphoma	University of Washington	P1	CC (43)
Inno-206 ALK-Positive Large B-Cell Lymphoma	University of Washington	P1	CC (43)
Interleukin 18 (recombinant human mutein clone ST-067) Plasma Cell Myeloma	University of Washington	P1	CC (43)
Niraparib BRCA-Associated Malignant Neoplasm	University of Washington	P1	CC (43)
Niraparib Familial Ovarian Carcinoma	University of Washington	P1	CC (43)
Niraparib Hereditary Breast Carcinoma	University of Washington	P1	CC (43)
Obinutuzumab ALK-Positive Large B-Cell Lymphoma	University of Washington	P1	CC (43)
Obinutuzumab Gray-Zone Lymphoma	University of Washington	P1	CC (43)

Showing 251 to 275 of 303 assets

PreviousPage 11 of 13Next